Work

Figure S3 from Targeting Semaphorin 7a Signaling in Preclinical Models of Endocrine Therapy–Resistant Breast Cancer

Year: 2026

Type: other

Abstract: Figure S3 shows PIK3CA mutation status across cell lines, IC50 curves for PI3K inhibitors in ER+ cell lines, cell viability using PI3K inhibitors, and pAKT levels after PI3K inhibitor treatment.

DOI: 10.1158/1535-7163.33414252

Authors: Rachel N. Steinmetz, Veronica Wessells, Heather Fairchild, Virgina F. Borges, Traci R. Lyons

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7205017107

Cites:

Cited by:

Related to: